Shots:
- Teva & Blackstone Life Sciences have entered a four-year strategic funding agreement to support the continued clinical development of duvakitug
- As per the deal, Blackstone will provide $400M to Teva over four years to fund duvakitug development, while Blackstone will receive potential milestone payment subject to FDA approval, & additional commercial milestones, as well as low single-digit royalties on global sales
- Duvakitug is a TL1A-targeting human mAb that is being co-developed by Teva & Sanofi & is currently in P-III trials for Ulcerative Colitis & Crohn’s Disease
Ref: Teva | Image: Teva & Blackstone | Press Release
Related News: Teva and Sanofi Report P-IIb (RELIEVE UCCD) LTE Study Data on Duvakitug in Inflammatory Bowel Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
